|
|
News Breaks | | | | November 8, 2012 | | 16:38 EDT |  | BPAX | BioSante reports Q3 EPS (27c), consensus (36c)
The decrease in the net loss was due primarily to lower clinical development expenses for LibiGel, its testosterone gel, during the most recent period as a result of the conclusion of all current LibiGel clinical studies. | |
|
News For BPAX From The Last 14 Days Check below for free stories on BPAX the last two weeks. |
|
|
| There are no results for BPAX |
|
|
|
|
|
|
